PortalPublikationenEpidemiology, biology and therapy of Merkel cell carcinoma:c...

Epidemiology, biology and therapy of Merkel cell carcinoma:conclusions from the EU project IMMOMEC

Standard

Epidemiology, biology and therapy of Merkel cell carcinoma:conclusions from the EU project IMMOMEC. / Becker, Jürgen C; Stang, Andreas; Hausen, Axel Zur; Fischer, Nicole; DeCaprio, James A; Tothill, Richard W; Lyngaa, Rikke; Hansen, Ulla Kring; Ritter, Cathrin; Nghiem, Paul; Bichakjian, Christopher K; Ugurel, Selma; Schrama, David.

in: CANCER IMMUNOL IMMUN, Jahrgang 67, Nr. 3, 03.2018, S. 341-351.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung

Harvard

Becker, JC, Stang, A, Hausen, AZ, Fischer, N, DeCaprio, JA, Tothill, RW, Lyngaa, R, Hansen, UK, Ritter, C, Nghiem, P, Bichakjian, CK, Ugurel, S & Schrama, D 2018, 'Epidemiology, biology and therapy of Merkel cell carcinoma:conclusions from the EU project IMMOMEC', CANCER IMMUNOL IMMUN, Jg. 67, Nr. 3, S. 341-351. https://doi.org/10.1007/s00262-017-2099-3

APA

Becker, J. C., Stang, A., Hausen, A. Z., Fischer, N., DeCaprio, J. A., Tothill, R. W., Lyngaa, R., Hansen, U. K., Ritter, C., Nghiem, P., Bichakjian, C. K., Ugurel, S., & Schrama, D. (2018). Epidemiology, biology and therapy of Merkel cell carcinoma:conclusions from the EU project IMMOMEC. CANCER IMMUNOL IMMUN, 67(3), 341-351. https://doi.org/10.1007/s00262-017-2099-3

Vancouver

Becker JC, Stang A, Hausen AZ, Fischer N, DeCaprio JA, Tothill RW et al. Epidemiology, biology and therapy of Merkel cell carcinoma:conclusions from the EU project IMMOMEC. CANCER IMMUNOL IMMUN. 2018 Mär;67(3):341-351. https://doi.org/10.1007/s00262-017-2099-3

Bibtex

@article{809645b7a8ff4693983b5d0a51780da8,
title = "Epidemiology, biology and therapy of Merkel cell carcinoma:conclusions from the EU project IMMOMEC",
abstract = "Merkel cell carcinoma (MCC) is a highly aggressive, often lethal neuroendocrine cancer. Its carcinogenesis may be either caused by the clonal integration of the Merkel cell polyomavirus into the host genome or by UV-induced mutations. Notably, virally-encoded oncoproteins and UV-induced mutations affect comparable signaling pathways such as RB restriction of cell cycle progression or p53 inactivation. Despite its low incidence, MCC recently received much attention based on its exquisite immunogenicity and the resulting major success of immune modulating therapies. Here, we summarize current knowledge on epidemiology, biology and therapy of MCC as conclusion of the project 'Immune Modulating strategies for treatment of Merkel Cell Carcinoma', which was funded over a 5-year period by the European Commission to investigate innovative immunotherapies for MCC.",
keywords = "Journal Article, Review",
author = "Becker, {J{\"u}rgen C} and Andreas Stang and Hausen, {Axel Zur} and Nicole Fischer and DeCaprio, {James A} and Tothill, {Richard W} and Rikke Lyngaa and Hansen, {Ulla Kring} and Cathrin Ritter and Paul Nghiem and Bichakjian, {Christopher K} and Selma Ugurel and David Schrama",
year = "2018",
month = mar,
doi = "10.1007/s00262-017-2099-3",
language = "English",
volume = "67",
pages = "341--351",
journal = "CANCER IMMUNOL IMMUN",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "3",

}

RIS

TY - JOUR

T1 - Epidemiology, biology and therapy of Merkel cell carcinoma:conclusions from the EU project IMMOMEC

AU - Becker, Jürgen C

AU - Stang, Andreas

AU - Hausen, Axel Zur

AU - Fischer, Nicole

AU - DeCaprio, James A

AU - Tothill, Richard W

AU - Lyngaa, Rikke

AU - Hansen, Ulla Kring

AU - Ritter, Cathrin

AU - Nghiem, Paul

AU - Bichakjian, Christopher K

AU - Ugurel, Selma

AU - Schrama, David

PY - 2018/3

Y1 - 2018/3

N2 - Merkel cell carcinoma (MCC) is a highly aggressive, often lethal neuroendocrine cancer. Its carcinogenesis may be either caused by the clonal integration of the Merkel cell polyomavirus into the host genome or by UV-induced mutations. Notably, virally-encoded oncoproteins and UV-induced mutations affect comparable signaling pathways such as RB restriction of cell cycle progression or p53 inactivation. Despite its low incidence, MCC recently received much attention based on its exquisite immunogenicity and the resulting major success of immune modulating therapies. Here, we summarize current knowledge on epidemiology, biology and therapy of MCC as conclusion of the project 'Immune Modulating strategies for treatment of Merkel Cell Carcinoma', which was funded over a 5-year period by the European Commission to investigate innovative immunotherapies for MCC.

AB - Merkel cell carcinoma (MCC) is a highly aggressive, often lethal neuroendocrine cancer. Its carcinogenesis may be either caused by the clonal integration of the Merkel cell polyomavirus into the host genome or by UV-induced mutations. Notably, virally-encoded oncoproteins and UV-induced mutations affect comparable signaling pathways such as RB restriction of cell cycle progression or p53 inactivation. Despite its low incidence, MCC recently received much attention based on its exquisite immunogenicity and the resulting major success of immune modulating therapies. Here, we summarize current knowledge on epidemiology, biology and therapy of MCC as conclusion of the project 'Immune Modulating strategies for treatment of Merkel Cell Carcinoma', which was funded over a 5-year period by the European Commission to investigate innovative immunotherapies for MCC.

KW - Journal Article

KW - Review

U2 - 10.1007/s00262-017-2099-3

DO - 10.1007/s00262-017-2099-3

M3 - SCORING: Review article

C2 - 29188306

VL - 67

SP - 341

EP - 351

JO - CANCER IMMUNOL IMMUN

JF - CANCER IMMUNOL IMMUN

SN - 0340-7004

IS - 3

ER -